Search
ISSN:
eISSN:
Disciplines
(Field of Science):
- biomedical engineering (Engineering and Technology)
- medical biology (Medical and Health Sciences )
- pharmacology and pharmacy (Medical and Health Sciences )
- medical sciences (Medical and Health Sciences )
- health sciences (Medical and Health Sciences )
- biotechnology (Natural sciences)
- biological sciences (Natural sciences)
- chemical sciences (Natural sciences)
(Field of Science)
Ministry points: Help
| Year | Points | List |
|---|---|---|
| Year 2024 | 100 | Ministry scored journals list 2024 |
| Year | Points | List |
|---|---|---|
| 2024 | 100 | Ministry scored journals list 2024 |
| 2023 | 100 | Ministry Scored Journals List |
| 2022 | 100 | Ministry Scored Journals List 2019-2022 |
| 2021 | 100 | Ministry Scored Journals List 2019-2022 |
| 2020 | 100 | Ministry Scored Journals List 2019-2022 |
| 2019 | 100 | Ministry Scored Journals List 2019-2022 |
| 2018 | 30 | A |
| 2017 | 30 | A |
| 2016 | 30 | A |
| 2015 | 30 | A |
| 2014 | 30 | A |
| 2013 | 30 | A |
| 2012 | 30 | A |
| 2011 | 30 | A |
| 2010 | 27 | A |
Model:
Points CiteScore:
| Year | Points |
|---|---|
| Year 2022 | 9.8 |
| Year | Points |
|---|---|
| 2022 | 9.8 |
| 2021 | 8.3 |
| 2020 | 6.2 |
| 2019 | 5.4 |
| 2018 | 6 |
| 2017 | 6.2 |
| 2016 | 5.4 |
| 2015 | 5.1 |
| 2014 | 6.5 |
| 2013 | 6.8 |
| 2012 | 5.6 |
| 2011 | 4.8 |
Impact Factor:
Sherpa Romeo:
Papers published in journal
Filters
total: 3
Catalog Journals
-
Pre-clinical evaluation of 1-nitroacridine derived chemotherapeutic agent that has preferential cytotoxic activity towards prostate cancer
PublicationPraca zawiera wyniki badań przedklinicznych pochodnej 1-nitroakrydyny C-1748 wobec komórek ludzkiego raka prostaty CaP in vitro, jak i przeszczepialnego na zwierzęta. W oparciu o fosforylację histonu H2AX jako markera podwójnych cięć DNA wykazano, że C-1748 jest bardziej aktywny w komórkach CaP niż HL60. Zidentyfikowano poza tym receptor androgenny (AR) jako cel molekularny badanego związku. W doświadczeniach na zwierzętach stwierdzono...
-
Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis
PublicationAntitumor imidazoacridinone C-1311 is a DNA-reactive topoisomerase II and FLT3 receptor tyrosine kinase inhibitor. Here, we demonstrate the mechanism of C-1311 inhibitory action on novel targets: hypoxia-inducible factor-1α (HIF-1α), vascular-endothelial growth factor (VEGF), and angiogenesis. In a cell-free system, C-1311 prevented HIF-1α binding to an oligonucleotide encompassing a canonical hypoxia-responsive element (HRE),...
-
Human UDP-Glucuronosyltransferases: Effects of altered expression in breast and pancreatic cancer cell lines.
PublicationIncreased aerobic glycolysis and de novo lipid biosynthesis are common characteristics of invasive cancers. UDP-glucuronosyltransferases (UGTs) are phase II drug metabolizing enzymes that in normal cells possess the ability to glucuronidate these lipids and speed their excretion; however, de-regulation of these enzymes in cancer cells can lead to an accumulation of bioactive lipids, which further fuels cancer progression. We hypothesize...
seen 338 times